📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
18
UTHR Latest News & AI Sentiment Analysis
2 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 4 ARTICLES
United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged (NASDAQ:UTHR)
United Therapeutics reported Q2 2026 revenue of $783M while maintaining its full-year guidance unchanged, signaling management...
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript
UTHR released Q2 2026 earnings results via earnings call transcript on August 5, 2026. The headline provides minimal detail on actual...
United Therapeutics buys Thymmune Therapeutics
United Therapeutics (UTHR) has announced an acquisition of Thymmune Therapeutics, a move that signals continued M&A activity within the...
United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics (UTHR) has acquired Thymmune Therapeutics, a preclinical-stage biotech firm focused on regenerative thymic cell...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice